Published: Guidance, quality standards and advice

Showing 11 to 20 of 42

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	TA897	6 June 2023	6 June 2023
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA889	17 May 2023	17 May 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	TA870	22 February 2023	22 February 2023
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA841	22 November 2022	22 November 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	TA783	13 April 2022	13 April 2022
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment)	DG47	30 March 2022	30 March 2022
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)	TA771	9 February 2022	9 February 2022
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable	TA763	2 February 2022	2 February 2022
clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia	MIB278	30 November 2021	30 November 2021
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA726	22 September 2021	22 September 2021